ARID2

Summary

ARID2 (AT-rich interaction domain 2, HGNC:18037) is a protein-coding gene on chromosome 12q12, encoding AT-rich interactive domain-containing protein 2 (Q68CP9). Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). It is a selective cancer dependency (DepMap: 33.9% of cell lines) and haploinsufficient (ClinGen: sufficient evidence).

This gene encodes a member of the AT-rich interactive domain (ARID)-containing family of DNA-binding proteins. Members of the ARID family have roles in embryonic patterning, cell lineage gene regulation, cell cycle control, transcriptional regulation and chromatin structure modification. This protein functions as a subunit of the polybromo- and BRG1-associated factor or PBAF (SWI/SNF-B) chromatin remodeling complex which facilitates ligand-dependent transcriptional activation by nuclear receptors. Mutations in this gene are associated with hepatocellular carcinomas. A pseudogene of this gene is found on chromosome1.

Source: NCBI Gene 196528 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Coffin-Siris syndrome (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 16
• Clinical variants (ClinVar): 585 total — 76 pathogenic, 35 likely-pathogenic
• Phenotypes (HPO): 103
• Druggable target: yes
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 21 cancer types
• Cancer dependency (DepMap): dependent in 33.9% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_152641

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18037
Approved symbol	ARID2
Name	AT-rich interaction domain 2
Location	12q12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1557, DKFZp686G052, FLJ30619, BAF200, SMARCF3, ZIPZAP, p200
Ensembl gene	ENSG00000189079
Ensembl biotype	protein_coding
OMIM	609539
Entrez	196528

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 9 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000334344, ENST00000422737, ENST00000426776, ENST00000427628, ENST00000444670, ENST00000457135, ENST00000477947, ENST00000479608, ENST00000480128, ENST00000700074, ENST00000851072, ENST00000859902, ENST00000859903, ENST00000956309

RefSeq mRNA: 2 — MANE Select: NM_152641 NM_001347839, NM_152641

CCDS: CCDS31783

Canonical transcript exons

ENST00000334344 — 21 exons

Exon	Start	End
ENSE00001238746	45836741	45836991
ENSE00001420131	45821420	45821487
ENSE00001426558	45836589	45836655
ENSE00003460259	45893420	45893543
ENSE00003468581	45893630	45893721
ENSE00003486216	45811418	45811551
ENSE00003492003	45892011	45892096
ENSE00003518023	45839329	45839496
ENSE00003518306	45848836	45848970
ENSE00003521642	45846856	45846937
ENSE00003523900	45817670	45817888
ENSE00003532308	45849580	45849776
ENSE00003540607	45837498	45837707
ENSE00003561016	45837321	45837417
ENSE00003564878	45860801	45860949
ENSE00003590472	45850036	45852896
ENSE00003672262	45891780	45891918
ENSE00003843639	45904934	45908037
ENSE00003978763	45730044	45730137
ENSE00003978764	45731217	45731314
ENSE00004283644	45729706	45729928

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 95.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.5302 / max 146.6726, expressed in 1751 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
125152	6.0995	1583
125150	2.8760	1350
125151	1.2583	600
125155	0.5199	146
125153	0.5139	272
125154	0.2155	97
125160	0.0471	4

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	95.74	gold quality
pancreatic ductal cell	CL:0002079	94.91	gold quality
secondary oocyte	CL:0000655	94.44	gold quality
oocyte	CL:0000023	90.93	gold quality
bone marrow cell	CL:0002092	90.50	gold quality
kidney epithelium	UBERON:0004819	89.90	silver quality
thymus	UBERON:0002370	89.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.50	gold quality
oviduct epithelium	UBERON:0004804	88.29	gold quality
ventricular zone	UBERON:0003053	88.23	gold quality
nasal cavity epithelium	UBERON:0005384	87.69	silver quality
colonic epithelium	UBERON:0000397	87.54	gold quality
ganglionic eminence	UBERON:0004023	87.43	gold quality
trabecular bone tissue	UBERON:0002483	87.41	gold quality
calcaneal tendon	UBERON:0003701	87.06	gold quality
bone marrow	UBERON:0002371	86.98	gold quality
ileal mucosa	UBERON:0000331	86.87	gold quality
nipple	UBERON:0002030	86.78	gold quality
lower esophagus mucosa	UBERON:0035834	86.59	gold quality
tibialis anterior	UBERON:0001385	86.54	silver quality
adrenal tissue	UBERON:0018303	86.33	gold quality
sural nerve	UBERON:0015488	85.93	gold quality
tonsil	UBERON:0002372	85.81	gold quality
testis	UBERON:0000473	85.66	gold quality
mucosa of paranasal sinus	UBERON:0005030	85.24	gold quality
epithelium of nasopharynx	UBERON:0001951	85.10	gold quality
cardia of stomach	UBERON:0001162	85.05	gold quality
corpus callosum	UBERON:0002336	84.91	gold quality
left testis	UBERON:0004533	84.85	gold quality
cortical plate	UBERON:0005343	84.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

309 targeting ARID2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-9-3P	99.96	70.88	2068

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 33.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 34)

• zipzap may serve as a transcription co-activator for the regulation of cardiac gene expression (PMID:16782067)
• 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype. (PMID:21822264)
• we summarize the current knowledge about the relevance of ARID2 in Hepatocellular carcinoma and the implication in future patient care (PMID:22095441)
• Recurrent inactivating mutations of ARID2 is associated with non-small cell lung carcinoma. (PMID:23047306)
• Mutations in ARID2 gene is associated with microsatellite unstable colorectal cancer. (PMID:24382590)
• The subsequent validation study on 68 LCBs identified recurrent mutations in TERT promoter, chromatin regulators (BAP1, PBRM1 and ARID2), a synapse organization gene (PCLO), IDH genes and KRAS. (PMID:25636086)
• loss of ARID2 protein expression may be associated with recurrence of hepatocellular carcinoma (PMID:25701229)
• This is the first report of mutations in ARID2 associated with developmental delay and intellectual disabilities . (PMID:26238514)
• Arid2 role in genome-wide transcriptional regulation by SWI/SNF complexes. (PMID:26716708)
• These findings highlight the potential role of ARID2 as a tumor growth suppressor in hepatocellular carcinoma (PMID:27351279)
• study identifies mutations in the ARID2 gene as a novel and rare cause for a CSS-like phenotype and enlarges the list of CSS-like genes (PMID:28124119)
• ARID2 knockout could contribute to disruption of DNA repair process. (PMID:28238438)
• Baf200 and Rad51 are present in the same complex and that this interaction is mediated by C-terminal sequences in both proteins. (PMID:28381560)
• We present a 4-year-old girl with delayed neuromotor development, short stature of prenatal onset, and specific behavioral and craniofacial features harboring an intragenic deletion in the ARID2 gene. The phenotype confirmed the major features of the recently described ARID2-related intellectual disability syndrome. (PMID:28884947)
• Mutations in or involving the ARID2 gene were identified in the patients with the features resembling Coffin-Siris syndrome. (PMID:29698805)
• The binding between HBc and BAF200 was of vital importance to HBc mediated downregulation of interferon-induced transmembrane protein 1 (IFITM1) expression. (PMID:31075894)
• Long non-coding RNA Arid2-IR affects advanced glycation end products-induced human retinal endothelial cell injury by binding to Smad3. (PMID:31912402)
• Association between ARID2 and RAS-MAPK pathway in intellectual disability and short stature. (PMID:33051312)
• Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. (PMID:33262464)
• ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. (PMID:33333124)
• Expression and prognostic values of ARID family members in breast cancer. (PMID:33592583)
• ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. (PMID:33742126)
• CREB1 acts via the miR922/ARID2 axis to enhance malignant behavior of liver cancer cells. (PMID:33786634)
• ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer. (PMID:34512623)
• BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. (PMID:35017665)
• Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. (PMID:35385731)
• ARID2 suppression promotes tumor progression and upregulates cytokeratin 8, 18 and beta-4 integrin expression in TP53-mutated tobacco-related oral cancer and has prognostic implications. (PMID:35869277)
• miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT. (PMID:36530029)
• USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination. (PMID:36567903)
• ARID2, a rare cause of Coffin-Siris syndrome: A novel microdeletion at 12q12q13.11 causing severe short stature and literature review. (PMID:36756859)
• Coffin-Siris Syndrome: Case Series of Three Patients and a Novel ARID2 Variant. (PMID:38182156)
• ARID2, a milder cause of Coffin-Siris Syndrome? Broadening the phenotype with 17 additional individuals. (PMID:38243407)
• ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes. (PMID:38341515)
• Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing. (PMID:39054516)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arid2	ENSDARG00000007413
mus_musculus	Arid2	ENSMUSG00000033237
rattus_norvegicus	Arid2	ENSRNOG00000004831
drosophila_melanogaster	Bap170	FBGN0042085
caenorhabditis_elegans		WBGENE00007433

Protein

Protein identifiers

AT-rich interactive domain-containing protein 2 — Q68CP9 (reviewed: Q68CP9)

Alternative names: BRG1-associated factor 200, Zinc finger protein with activation potential, Zipzap/p200

All UniProt accessions (6): A0A087WY37, A0A8V8TP93, F8VWP4, F8W108, F8WCU9, Q68CP9

UniProt curated annotations — full annotation on UniProt →

Function. Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes.

Subunit / interactions. Component of the SWI/SNF-B (PBAF) chromatin remodeling complex, at least composed of SMARCA4/BRG1, SMARCB1/BAF47/SNF5, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCE1/BAF57, SMARCD1/BAF60A, SMARCD2/BAF60B, perhaps SMARCD3/BAF60C, SMARCC1/BAF155, SMARCC2/BAF170, PBRM1/BAF180, ARID2/BAF200 and actin. Interacts with SRF. Forms complexes with SRF and SRF cofactors MYOCD, NKX2-5 and SRFBP1.

Subcellular location. Nucleus.

Tissue specificity. Highly expressed in heart.

Disease relevance. Coffin-Siris syndrome 6 (CSS6) [MIM:617808] A form of Coffin-Siris syndrome, a congenital multiple malformation syndrome with broad phenotypic and genetic variability. Cardinal features are intellectual disability, coarse facial features, hypertrichosis, and hypoplastic or absent fifth digit nails or phalanges. Additional features include malformations of the cardiac, gastrointestinal, genitourinary, and/or central nervous systems. Sucking/feeding difficulties, poor growth, ophthalmologic abnormalities, hearing impairment, and spinal anomalies are common findings. Both autosomal dominant and autosomal recessive inheritance patterns have been reported. CSS6 inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q68CP9-1	1	yes
Q68CP9-3	2

RefSeq proteins (2): NP_001334768, NP_689854* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001606	ARID_dom	Domain
IPR003150	DNA-bd_RFX	Domain
IPR013087	Znf_C2H2_type	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR036431	ARID_dom_sf	Homologous_superfamily
IPR052406	Chromatin_Remodeling_Comp	Family

Pfam: PF01388, PF02257

UniProt features (106 total): helix 30, sequence conflict 18, modified residue 10, compositionally biased region 9, region of interest 8, turn 8, strand 7, cross-link 7, sequence variant 2, initiator methionine 1, chain 1, short sequence motif 1, domain 1, DNA-binding region 1, zinc finger region 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7VDV	ELECTRON MICROSCOPY	3.4
7Y8R	ELECTRON MICROSCOPY	4.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68CP9-F1	52.30	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (17): 2, 4, 631, 635, 653, 689, 692, 1300, 1391, 1496, 7, 15, 119, 555, 1701, 1716, 1731

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-3214858	RMTs methylate histone arginines
R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
R-HSA-9933939	Formation of the polybromo-BAF (pBAF) complex
R-HSA-212436	Generic Transcription Pathway
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8878171	Transcriptional regulation by RUNX1

MSigDB gene sets: 600 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_REGULATION_OF_DNA_RECOMBINATION, WANG_CLIM2_TARGETS_UP, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_CORONARY_VASCULATURE_DEVELOPMENT, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_GROWTH, chr12q12, TATTATA_MIR374, GOBP_ARTERY_DEVELOPMENT, GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR_VIA_HOMOLOGOUS_RECOMBINATION, GOBP_MUSCLE_CELL_PROLIFERATION

GO Biological Process (22): heart morphogenesis (GO:0003007), nucleosome disassembly (GO:0006337), chromatin remodeling (GO:0006338), regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of cell population proliferation (GO:0008285), regulation of mitotic metaphase/anaphase transition (GO:0030071), negative regulation of cell migration (GO:0030336), homeostatic process (GO:0042592), positive regulation of T cell differentiation (GO:0045582), positive regulation of cell differentiation (GO:0045597), positive regulation of myoblast differentiation (GO:0045663), embryonic organ development (GO:0048568), cardiac muscle cell proliferation (GO:0060038), coronary artery morphogenesis (GO:0060982), regulation of G0 to G1 transition (GO:0070316), positive regulation of double-strand break repair via homologous recombination (GO:1905168), regulation of G1/S transition of mitotic cell cycle (GO:2000045), positive regulation of double-strand break repair (GO:2000781), regulation of nucleotide-excision repair (GO:2000819), chromatin organization (GO:0006325), regulation of DNA-templated transcription (GO:0006355), circulatory system development (GO:0072359)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (8): kinetochore (GO:0000776), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), plasma membrane (GO:0005886), nuclear matrix (GO:0016363), SWI/SNF complex (GO:0016514), RSC-type complex (GO:0016586)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Transcriptional regulation by RUNX1	1
SWI/SNF chromatin remodelers	1
RNA Polymerase II Transcription	1
Chromatin organization	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of mitotic cell cycle phase transition	2
nuclear lumen	2
SWI/SNF superfamily-type complex	2
heart development	1
animal organ morphogenesis	1
protein-DNA complex disassembly	1
nucleosome organization	1
chromatin organization	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
metaphase/anaphase transition of mitotic cell cycle	1
regulation of metaphase/anaphase transition of cell cycle	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
biological_process	1
T cell differentiation	1
regulation of T cell differentiation	1
positive regulation of lymphocyte differentiation	1
positive regulation of T cell activation	1
cell differentiation	1
regulation of cell differentiation	1
positive regulation of cellular process	1
positive regulation of developmental process	1
myoblast differentiation	1
positive regulation of cell differentiation	1
regulation of myoblast differentiation	1
embryo development	1
animal organ development	1
striated muscle cell proliferation	1
cardiac muscle tissue growth	1
artery morphogenesis	1
coronary vasculature morphogenesis	1
regulation of cell cycle process	1
G0 to G1 transition	1
double-strand break repair via homologous recombination	1

Protein interactions and networks

STRING

1775 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARID2	PBRM1	Q86U86	999
ARID2	BRD7	Q9NPI1	997
ARID2	SMARCA4	P51532	996
ARID2	SMARCB1	Q12824	995
ARID2	PHF10	Q8WUB8	995
ARID2	SMARCE1	Q969G3	992
ARID2	ARID1A	O14497	989
ARID2	ARID1B	Q8NFD5	985
ARID2	SMARCC1	Q92922	964
ARID2	SMARCC2	Q8TAQ2	945
ARID2	BRD9	Q9H8M2	933
ARID2	ACTL6A	O96019	932
ARID2	DPF2	Q92785	929
ARID2	SMARCA2	P51531	925
ARID2	ACTL6B	O94805	836

IntAct

165 interactions, top by confidence:

A	B	Type	Score
SMARCB1	ARID2	psi-mi:“MI:0915”(physical association)	0.890
SMARCB1	ARID1A	psi-mi:“MI:0914”(association)	0.860
SMARCE1	ARID1A	psi-mi:“MI:0914”(association)	0.840
NUP50	KPNA4	psi-mi:“MI:0914”(association)	0.830
PBRM1	SMARCA4	psi-mi:“MI:0914”(association)	0.800
SMARCE1	ARID2	psi-mi:“MI:0915”(physical association)	0.800
SMARCC1	ARID1A	psi-mi:“MI:0914”(association)	0.790
SMARCD1	ARID1A	psi-mi:“MI:0914”(association)	0.790
SMARCC2	ARID1A	psi-mi:“MI:0914”(association)	0.790
ARID2	SMARCA4	psi-mi:“MI:0915”(physical association)	0.770
ARID2	SMARCA4	psi-mi:“MI:0914”(association)	0.770
SS18	ARID1A	psi-mi:“MI:0914”(association)	0.760
SMARCE1	SMARCA2	psi-mi:“MI:0914”(association)	0.730
SMARCA4	ACTL6A	psi-mi:“MI:0914”(association)	0.670

BioGRID (250): ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Co-fractionation), ARID2 (Co-fractionation), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ARID2 (Affinity Capture-MS)

ESM2 similar proteins: A9LNK9, B2D6P4, E9Q7E2, G4N3L5, G5ED29, O15350, O45211, O61707, O95104, P14003, P15330, P20227, P23645, P29303, P34545, P47238, P49880, P53361, P98149, Q02926, Q0DA50, Q1LZF1, Q21955, Q22366, Q22703, Q29A33, Q3L1C9, Q4V3C1, Q61L47, Q68CP9, Q6C7K8, Q6E2N3, Q6YGZ4, Q7TSH6, Q7ZX03, Q8QGQ6, Q8SWR8, Q91YA8, Q91YB0, Q91YB2

Diamond homologs: A0A0K3AXH1, A2BEA6, A2CG63, A6NKF2, A6PWV5, E1BLP6, E2R9X2, E7F888, E9Q7E2, F8VPQ2, O13953, O74365, P29374, Q03989, Q14865, Q24573, Q3SWY1, Q3U108, Q4H3P5, Q4LE39, Q4V3E2, Q54RM0, Q5XGD9, Q5ZJ69, Q62431, Q68CP9, Q6GQD7, Q8BM75, Q8IN94, Q8IVW6, Q8MQH7, Q94C32, Q99856, Q9JKB5, Q9Z1N7, C0SUW7, Q0WNR6, Q940Y3, Q9LTT3, Q9SGS2

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ARID2	“form complex”	“SWI/SNF complex”	binding
ARID2	“form complex”	“SWI/SNF ACTL6B varian”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 148 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of the canonical BAF (cBAF) complex	13	80.9×	1e-21
Formation of the polybromo-BAF (pBAF) complex	13	80.9×	1e-21
Formation of the embryonic stem cell BAF (esBAF) complex	13	76.6×	3e-21
Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	16	71.7×	5e-25
Formation of the non-canonical BAF (ncBAF) complex	10	65.9×	2e-15
Regulation of endogenous retroelements	14	50.6×	2e-19
Regulation of MITF-M-dependent genes involved in pigmentation	17	44.3×	3e-22
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	11	32.4×	8e-13

GO biological processes:

GO term	Partners	Fold	FDR
regulation of G0 to G1 transition	16	81.1×	1e-25
regulation of nucleotide-excision repair	16	72.4×	1e-24
regulation of mitotic metaphase/anaphase transition	16	59.6×	4e-23
nucleosome disassembly	8	48.3×	2e-10
positive regulation of double-strand break repair	16	41.4×	4e-20
positive regulation of T cell differentiation	12	41.1×	5e-15
regulation of G1/S transition of mitotic cell cycle	16	36.9×	3e-19
NLS-bearing protein import into nucleus	6	36.2×	7e-07

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 21 cancer types — CHOL, CSCC, ESCA, ESCC, GB, GBC, HCC, HNSC, LGGNOS, LUAD, MBL, MEL…(+9 more).

Clinical variants and AI predictions

ClinVar

585 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	76
Likely pathogenic	35
Uncertain significance	285
Likely benign	111
Benign	21

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1034327	NM_152641.4(ARID2):c.5026C>T (p.Gln1676Ter)	Pathogenic
1170954	NM_152641.4(ARID2):c.118dup (p.Val40fs)	Pathogenic
1170956	NM_152641.4(ARID2):c.2401_2402del (p.Met801fs)	Pathogenic
1170957	NM_152641.4(ARID2):c.3301_3302insAGGT (p.Val1101fs)	Pathogenic
1170958	NM_152641.4(ARID2):c.3814C>T (p.Arg1272Ter)	Pathogenic
1170959	NM_152641.4(ARID2):c.4732C>T (p.Gln1578Ter)	Pathogenic
1170960	NM_152641.3:c.(705+1_706-1)_(1330+1_1331-1)del	Pathogenic
1170961	GRCh37/hg19 12q12(chr12:46168172-46304719)x1	Pathogenic
1170962	GRCh37/hg19 12q12(chr12:46150008-46321670)x1	Pathogenic
1177333	NM_152641.4(ARID2):c.156_157del (p.Arg53fs)	Pathogenic
1177334	NM_152641.4(ARID2):c.1262_1265dup (p.Tyr423fs)	Pathogenic
1177336	NM_152641.4(ARID2):c.1580+1G>A	Pathogenic
1177337	NM_152641.4(ARID2):c.2458C>T (p.Gln820Ter)	Pathogenic
1196352	NM_152641.4(ARID2):c.5029C>T (p.Arg1677Ter)	Pathogenic
1198066	NM_152641.4(ARID2):c.5132_5135dup (p.Ser1713fs)	Pathogenic
1285520	NM_152641.4(ARID2):c.4540_4541delinsGAA (p.Thr1514fs)	Pathogenic
1321937	NM_152641.4(ARID2):c.2734C>T (p.Gln912Ter)	Pathogenic
1343246	NM_152641.4(ARID2):c.1331-1G>C	Pathogenic
1526286	NC_000012.12:g.45690000_45750000del	Pathogenic
1675488	NM_152641.4(ARID2):c.3065dup (p.Pro1023fs)	Pathogenic
1679288	NM_152641.4(ARID2):c.4210dup (p.Gln1404fs)	Pathogenic
1684625	NM_152641.4(ARID2):c.2377C>T (p.Gln793Ter)	Pathogenic
1699019	NM_152641.4(ARID2):c.4255_4256del (p.Pro1419fs)	Pathogenic
1710278	NM_152641.4(ARID2):c.675G>A (p.Trp225Ter)	Pathogenic
1710463	NM_152641.4(ARID2):c.2767C>T (p.Gln923Ter)	Pathogenic
1711363	GRCh37/hg19 12q12(chr12:46230372-46233279)x1	Pathogenic
1802698	NM_152641.4(ARID2):c.1837C>T (p.Gln613Ter)	Pathogenic
1805865	NM_152641.4(ARID2):c.1334_1338del (p.Met445fs)	Pathogenic
1879230	NM_152641.4(ARID2):c.2164dup (p.Ser722fs)	Pathogenic
1879231	NM_152641.4(ARID2):c.3467del (p.Ile1156fs)	Pathogenic

SpliceAI

3962 predictions. Top by Δscore:

Variant	Effect	Δscore
12:45729925:GAGG:G	donor_gain	1.0000
12:45729927:GG:G	donor_gain	1.0000
12:45729928:GG:G	donor_gain	1.0000
12:45729929:G:GA	donor_loss	1.0000
12:45729929:G:GG	donor_gain	1.0000
12:45730134:GAAG:G	donor_gain	1.0000
12:45730136:AGG:A	donor_loss	1.0000
12:45730138:G:GA	donor_loss	1.0000
12:45811414:TCAGT:T	acceptor_loss	1.0000
12:45811415:CAGTT:C	acceptor_loss	1.0000
12:45811416:A:AG	acceptor_gain	1.0000
12:45811416:AG:A	acceptor_loss	1.0000
12:45811417:G:GG	acceptor_gain	1.0000
12:45811417:GTT:G	acceptor_gain	1.0000
12:45811550:GG:G	donor_gain	1.0000
12:45811551:GG:G	donor_gain	1.0000
12:45817668:A:AG	acceptor_gain	1.0000
12:45817669:G:GG	acceptor_gain	1.0000
12:45817669:GATT:G	acceptor_gain	1.0000
12:45817884:CGACA:C	donor_gain	1.0000
12:45817885:GACA:G	donor_gain	1.0000
12:45817885:GACAG:G	donor_gain	1.0000
12:45817886:ACA:A	donor_gain	1.0000
12:45817887:CA:C	donor_gain	1.0000
12:45817887:CAG:C	donor_loss	1.0000
12:45817888:AG:A	donor_loss	1.0000
12:45817889:G:A	donor_loss	1.0000
12:45817889:G:GG	donor_gain	1.0000
12:45817890:T:A	donor_loss	1.0000
12:45817891:AA:A	donor_loss	1.0000

AlphaMissense

11927 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:45729891:T:C	F19L	1.000
12:45729892:T:C	F19S	1.000
12:45729893:C:A	F19L	1.000
12:45729893:C:G	F19L	1.000
12:45729904:T:C	L23P	1.000
12:45729912:T:C	F26L	1.000
12:45729913:T:C	F26S	1.000
12:45729914:C:A	F26L	1.000
12:45729914:C:G	F26L	1.000
12:45729915:C:G	H27D	1.000
12:45730085:T:C	L45P	1.000
12:45730100:T:C	L50P	1.000
12:45730102:T:G	Y51D	1.000
12:45730112:T:A	V54D	1.000
12:45730127:G:A	G59E	1.000
12:45731218:T:A	V63D	1.000
12:45731235:T:A	W69R	1.000
12:45731235:T:C	W69R	1.000
12:45731236:G:C	W69S	1.000
12:45731237:G:C	W69C	1.000
12:45731237:G:T	W69C	1.000
12:45731307:T:G	Y93D	1.000
12:45811423:T:A	L97Q	1.000
12:45811423:T:C	L97P	1.000
12:45811431:T:G	Y100D	1.000
12:45811432:A:C	Y100S	1.000
12:45811436:G:C	E101D	1.000
12:45811436:G:T	E101D	1.000
12:45817733:T:C	L161S	1.000
12:45817745:T:C	L165P	1.000

dbSNP variants (sampled 300 via entrez): RS1000000554 (12:45832706 A>G), RS1000013070 (12:45878537 A>G), RS1000019278 (12:45848386 T>C,G), RS1000040257 (12:45824685 G>C), RS1000113455 (12:45750272 C>G,T), RS1000140169 (12:45781876 G>A), RS1000151069 (12:45824421 A>T), RS1000164772 (12:45880033 T>C), RS1000165902 (12:45853833 G>A), RS1000172394 (12:45788341 G>A), RS1000188408 (12:45898096 C>A), RS1000204008 (12:45905277 A>G), RS1000217964 (12:45860614 A>C,G), RS1000218482 (12:45830822 C>A,T), RS1000242878 (12:45813826 G>A)

Disease associations

OMIM: gene MIM:609539 | disease phenotypes: MIM:617808, MIM:135900, MIM:609943, MIM:614562, MIM:619681

GenCC curated gene-disease

Disease	Classification	Inheritance
Coffin-Siris syndrome	Strong	Autosomal dominant
Coffin-Siris syndrome 6	Strong	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Coffin-Siris syndrome	Definitive	AD

Mondo (10): Coffin-Siris syndrome 6 (MONDO:0033492), neurodevelopmental disorder (MONDO:0700092), chronic diarrheal disease (MONDO:0044751), microcephaly (MONDO:0001149), Coffin-Siris syndrome (MONDO:0015452), desmoplastic/nodular medulloblastoma (MONDO:0016711), autism spectrum disorder (MONDO:0005258), Coffin-Siris syndrome 1 (MONDO:0007617), dystonia, early-onset, and/or spastic paraplegia (MONDO:0859215), Castleman-Kojima disease (MONDO:0018702)

Orphanet (4): Coffin-Siris syndrome (Orphanet:1465), Desmoplastic/nodular medulloblastoma (Orphanet:251863), TAFRO syndrome (Orphanet:457077), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

103 total (30 of 103 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000028	Cryptorchidism
HP:0000047	Hypospadias
HP:0000085	Horseshoe kidney
HP:0000119	Abnormality of the genitourinary system
HP:0000154	Wide mouth
HP:0000175	Cleft palate
HP:0000179	Thick lower lip vermilion
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000278	Retrognathia
HP:0000280	Coarse facial features
HP:0000286	Epicanthus
HP:0000289	Broad philtrum
HP:0000294	Low anterior hairline
HP:0000322	Short philtrum
HP:0000347	Micrognathia
HP:0000348	High forehead
HP:0000358	Posteriorly rotated ears
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000405	Conductive hearing impairment
HP:0000455	Broad nasal tip
HP:0000463	Anteverted nares
HP:0000486	Strabismus
HP:0000494	Downslanted palpebral fissures
HP:0000505	Visual impairment
HP:0000508	Ptosis
HP:0000545	Myopia
HP:0000574	Thick eyebrow

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST000461_8	Hippocampal atrophy	8.000000e-06
GCST005316_367	Intelligence (MTAG)	2.000000e-08
GCST006291_122	Spherical equivalent or myopia (age of diagnosis)	7.000000e-15
GCST006613_83	Triglycerides	6.000000e-11
GCST007565_168	Morning person	5.000000e-17
GCST007565_34	Morning person	8.000000e-17
GCST007576_341	Chronotype	5.000000e-17
GCST010002_216	Refractive error	2.000000e-29
GCST010142_31	Fish- and plant-related diet	7.000000e-09
GCST010244_377	Triglyceride levels	9.000000e-11
GCST010320_91	PR interval	2.000000e-09
GCST010321_72	PR interval	2.000000e-10
GCST90002383_1	Hematocrit	1.000000e-14
GCST90002384_305	Hemoglobin	4.000000e-12
GCST90002390_56	Mean corpuscular hemoglobin	3.000000e-09
GCST90002403_447	Red blood cell count	5.000000e-18

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0005039	hippocampal atrophy
EFO:0004337	intelligence
EFO:0004847	age at onset
EFO:0004530	triglyceride measurement
EFO:0008328	chronotype measurement
EFO:0008111	diet measurement
EFO:0004462	PR interval
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0004305	erythrocyte count

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D065886	Neurodevelopmental Disorders	F03.625
C536436	Coffin-Siris syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725016 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.32	Kd	4847	nM	CHEMBL5653589
5.30	ED50	5023	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147887: Binding affinity to human ARID2 incubated for 45 mins by Kinobead based pull down assay	kd	4.8469	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, increases expression, affects cotreatment, decreases expression, affects expression	10
trichostatin A	decreases expression, affects expression, affects cotreatment	4
bisphenol A	affects methylation, increases expression, increases methylation	2
(+)-JQ1 compound	affects expression, increases reaction, decreases expression	2
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
Formaldehyde	decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
TAK-243	decreases sumoylation	1
methylmercuric chloride	decreases expression	1
lasiocarpine	decreases expression, increases metabolic processing	1
triphenyl phosphate	affects expression	1
riddelliine	decreases expression, increases metabolic processing	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Irinotecan	decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	decreases expression	1
Panobinostat	affects expression, increases reaction	1
Acetaminophen	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5650929	Binding	Binding affinity to human ARID2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

486 cell lines: 464 induced pluripotent stem cell, 12 cancer cell line, 7 transformed cell line, 3 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1105	CAL-12T	Cancer cell line	Male
CVCL_1134	COLO 792	Cancer cell line	Male
CVCL_3947	SNU-354	Cancer cell line	Male
CVCL_9S58	HPSI0114i-kolf_2-C1	Induced pluripotent stem cell	Male
CVCL_A4II	CAL-12T KRAS (G12C/+)	Cancer cell line	Male
CVCL_AE29	HPSI0114i-kolf_2	Induced pluripotent stem cell	Male
CVCL_B1JY	Abcam HeLa ARID2 KO	Cancer cell line	Female
CVCL_B5P3	KOLF2.1J	Induced pluripotent stem cell	Male
CVCL_B7JK	SCLC-J1	Cancer cell line	Male
CVCL_C7TY	KOLF2.1J PPM1H KO	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

229 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT03876717	PHASE4	COMPLETED	Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea
NCT07436104	PHASE4	COMPLETED	Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT01585025	PHASE2	COMPLETED	Obeticholic Acid in Bile Acid Diarrhoea
NCT03270085	PHASE2	COMPLETED	Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
NCT05130047	PHASE2	COMPLETED	Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
NCT05690321	PHASE2	COMPLETED	Opium Tincture Against Chronic Diarrhea - Patients
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06960369	PHASE1	RECRUITING	Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers